Amedeo Smart

Free Medical Literature Service


 

Amedeo

Peptic Ulcer

  Free Subscription

Articles published in
Aliment Pharmacol Ther
    September 2021
  1. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018).
    Aliment Pharmacol Ther. 2021 Sep 3. doi: 10.1111/apt.16565.
    >> Share

  2. BASNAYAKE C, Geeraerts A, Pauwels A, Koek G, et al
    Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment.
    Aliment Pharmacol Ther. 2021;54:755-778.
    >> Share

    August 2021
  3. ZAMANI M, Alizadeh-Tabari S, Hasanpour AH, Eusebi LH, et al
    Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications.
    Aliment Pharmacol Ther. 2021 Aug 26. doi: 10.1111/apt.16585.
    >> Share

  4. ARAI J, Aoki T, Hayakawa Y, Niikura R, et al
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm.
    Aliment Pharmacol Ther. 2021;54:528-529.
    >> Share

  5. LIU Y, Chen M
    Letter: association between the risk of microscopic colitis and use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;54:526-527.
    >> Share

  6. CHEN L, Glance S, Garg M
    Letter: response of eosinophilic oesophagitis to proton pump inhibitor therapy-the importance of biopsies at index endoscopy.
    Aliment Pharmacol Ther. 2021;54:521-522.
    >> Share

  7. LUI TKL, Leung WK
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:530-531.
    >> Share

  8. KATZ P
    Editorial: non-erosive reflux disease is often not GERD-time to change the definition or abandon the term?
    Aliment Pharmacol Ther. 2021;54:493-494.
    >> Share

    July 2021
  9. KIM YD, Wang J, Shibli F, Poels KE, et al
    No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
    Aliment Pharmacol Ther. 2021 Jul 12. doi: 10.1111/apt.16464.
    >> Share

  10. ROGERS BD, Gyawali CP
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers?
    Aliment Pharmacol Ther. 2021;54:188-189.
    >> Share

  11. FRAZZONI M, Frazzoni L, de Bortoli N, Savarino E, et al
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:190-191.
    >> Share

  12. OUDE NIJHUIS RAB, Sweis R, Abdul-Razakq H, Schuitenmaker JM, et al
    Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring.
    Aliment Pharmacol Ther. 2021;54:144-152.
    >> Share

    June 2021
  13. RIBOLSI M, Frazzoni M, Marabotto E, De Carlo G, et al
    Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus.
    Aliment Pharmacol Ther. 2021 Jun 28. doi: 10.1111/apt.16481.
    >> Share

  14. SALVO EM, Ferko NC, Cash SB, Gonzalez A, et al
    Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16407.
    >> Share

  15. YADAV Y, Talley NJ
    Editorial: microscopic colitis linked to NSAIDs but not proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;53:1324-1325.
    >> Share

    April 2021
  16. FRAZZONI M, Frazzoni L, De Bortoli N, Russo S, et al
    Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action.
    Aliment Pharmacol Ther. 2021 Apr 15. doi: 10.1111/apt.16371.
    >> Share

    March 2021
  17. EUSEBI LH, Telese A, Cirota GG, Haidry R, et al
    Systmatic review with meta-analysis: Risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2021 Mar 11. doi: 10.1111/apt.16321.
    >> Share

  18. HUSSAIN N, Shung DL
    Editorial: vitamin K antagonists versus direct oral anticoagulants in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2021;53:751-752.
    >> Share

  19. LABENZ C, Schattenberg JM
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:673.
    >> Share

  20. SUGIYAMA T
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view.
    Aliment Pharmacol Ther. 2021;53:671-672.
    >> Share

  21. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:665-666.
    >> Share

  22. CELSA C, Camma C
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle.
    Aliment Pharmacol Ther. 2021;53:663-664.
    >> Share

    February 2021
  23. ABDEL-AZIZ Y, Metz DC, Howden CW
    Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.
    Aliment Pharmacol Ther. 2021 Feb 16. doi: 10.1111/apt.16295.
    >> Share

    January 2021
  24. LEUNG WK, Cheung KS, Li B, Law SYK, et al
    Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2021 Jan 24. doi: 10.1111/apt.16272.
    >> Share

  25. GOURIOU C, Bouguen G, Lahmek P, Pelaquier A, et al
    Outcomes of upper gastrointestinal bleeding are similar between direct oral anticoagulants and vitamin K antagonists.
    Aliment Pharmacol Ther. 2021 Jan 5. doi: 10.1111/apt.16236.
    >> Share

    December 2020
  26. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Impact of proton pump inhibitors on cytochrome P450 activity assessed by (13) C-aminopyrine breath test in patients with cirrhosis.
    Aliment Pharmacol Ther. 2020 Dec 28. doi: 10.1111/apt.16239.
    >> Share

    November 2020
  27. CHAUDHARY S, Mackay D, Pell JP, Morris J, et al
    Upper gastrointestinal bleeding in Scotland 2000-2015: trends in demographics, aetiology and outcomes.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16170.
    >> Share

    September 2020
  28. VERMORKEN AJM, Zhu J, Cui Y
    Letter: does Helicobacter pylori infection limit the health effects of the Mediterranean diet?
    Aliment Pharmacol Ther. 2020;52:935-936.
    >> Share

  29. LEE PL, Suk FM, Kang YN
    Letter: does tranexamic acid reduce the need for surgery in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;52:1088-1089.
    >> Share

  30. MARCUS EA, Pisegna JR
    Editorial: tegoprazan-the newest advance in the management of acid-related diseases.
    Aliment Pharmacol Ther. 2020;52:1074-1075.
    >> Share

    August 2020
  31. MEI LI C, Brusselaers N
    Letter: safety of proton pump inhibitors during pregnancy-authors' reply.
    Aliment Pharmacol Ther. 2020;52:740-741.
    >> Share

  32. ACAR S, Keskin-Arslan E, Uysal N, Karadas B, et al
    Letter: safety of proton pump inhibitors during pregnancy.
    Aliment Pharmacol Ther. 2020;52:739.
    >> Share

    July 2020
  33. LABENZ C, Worns MA, Adarkwah CC, Galle PR, et al
    Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study.
    Aliment Pharmacol Ther. 2020 Jul 30. doi: 10.1111/apt.16008.
    >> Share

  34. CHO YK, Choi MG, Choi SC, Lee KM, et al
    Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
    Aliment Pharmacol Ther. 2020 Jul 23. doi: 10.1111/apt.15865.
    >> Share

  35. LASERNA-MENDIETA EJ, Casabona S, Guagnozzi D, Savarino E, et al
    Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry.
    Aliment Pharmacol Ther. 2020 Jul 17. doi: 10.1111/apt.15957.
    >> Share

  36. SCHNOLL-SUSSMAN F, Katz PO
    Letter: bone fracture risk among older long-term users of proton pump inhibitors. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:408.
    >> Share

  37. SUGIYAMA T
    Letter: bone fracture risk among older long-term users of proton pump inhibitors.
    Aliment Pharmacol Ther. 2020;52:407-408.
    >> Share

  38. MA ZF, Deraman MA, Coyle C, Lee YY, et al
    Editorial: simultaneous, prolonged monitoring of the acid pocket and oesophageal reflux. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:398-399.
    >> Share

  39. KATZ PO, Castell DO
    Editorial: simultaneous prolonged monitoring of the acid pocket and oesophageal reflux.
    Aliment Pharmacol Ther. 2020;52:397-398.
    >> Share

    June 2020
  40. YUAN J, Zhang C, Sparks JA, Malspeis S, et al
    Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.
    Aliment Pharmacol Ther. 2020 Jun 29. doi: 10.1111/apt.15834.
    >> Share

  41. PAPAEFTHYMIOU A, Doulberis M, Polyzos SA, Katsinelos P, et al
    Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma.
    Aliment Pharmacol Ther. 2020;51:1215-1216.
    >> Share

  42. GANTUYA B, El-Serag HB, Yamaoka Y
    Letter: are microbes other than Helicobacter pylori associated with gastric cancer? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1447-1449.
    >> Share

  43. HE C, Peng C, Xia Z, Lu N, et al
    Letter: are microbes other than Helicobacter pylori associated with gastric cancer?
    Aliment Pharmacol Ther. 2020;51:1446-1447.
    >> Share

  44. SUN Y
    Letter: Helicobacter pylori eradication treatment and the risk of oesophageal adenocarcinoma.
    Aliment Pharmacol Ther. 2020;51:1452-1453.
    >> Share

    May 2020
  45. TWUM-BARIMAH E, Abdelgadir I, Gordon M, Akobeng AK, et al
    Systematic review with meta-analysis: the efficacy of tranexamic acid in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2020 May 3. doi: 10.1111/apt.15761.
    >> Share

  46. ZHANG C, Li N, An Y
    Letter: the relationship between Helicobacter pylori and coronary heart disease.
    Aliment Pharmacol Ther. 2020;51:999.
    >> Share

    March 2020
  47. KUMAR S, Metz DC, Ginsberg GG, Kaplan DE, et al
    Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2020 Mar 4. doi: 10.1111/apt.15677.
    >> Share

    January 2020
  48. MACKE L, Schulz C, Koletzko L, Malfertheiner P, et al
    Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.
    Aliment Pharmacol Ther. 2020 Jan 28. doi: 10.1111/apt.15604.
    >> Share

  49. LI CM, Zhernakova A, Engstrand L, Wijmenga C, et al
    Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy.
    Aliment Pharmacol Ther. 2020 Jan 7. doi: 10.1111/apt.15610.
    >> Share

  50. MCPHERSON SJ, Hammond CJ
    Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2020;51:311-312.
    >> Share

  51. BARDOU M, Barkun AN
    Editorial: how can we best promote the routine use of scores that are accurate at predicting outcomes in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;51:305-306.
    >> Share

  52. PAPAEFTHYMIOU A, Doulberis M, Polyzos SA, Katsinelos P, et al
    Letter: Helicobacter pylori in proton pump inhibitor-associated biliary disease.
    Aliment Pharmacol Ther. 2020;51:313-314.
    >> Share

  53. STANLEY A
    Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding. Author's reply.
    Aliment Pharmacol Ther. 2020;51:312-313.
    >> Share

  54. KURLANDER JE, Rubenstein JH
    Editorial: moving towards the appropriate use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2020;51:175-176.
    >> Share

  55. SCHNOLL-SUSSMAN F, Katz PO
    Editorial: moving towards appropriate use of proton pump inhibitors. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:177.
    >> Share

  56. SCHEIMAN JM
    Commentary: cardioprotective aspirin and gastroduodenal ulcers.
    Aliment Pharmacol Ther. 2020;51:203.
    >> Share

    October 2019
  57. GHOSH G, Schnoll-Sussman F, Mathews S, Katz PO, et al
    Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns?
    Aliment Pharmacol Ther. 2019 Oct 30. doi: 10.1111/apt.15522.
    >> Share

  58. SAFFOURI E, Blackwell C, Laursen SB, Laine L, et al
    The Shock Index is not accurate at predicting outcomes in patients with upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2019 Oct 23. doi: 10.1111/apt.15541.
    >> Share

  59. GUO CG, Cheung KS, Zhang F, Chan EW, et al
    Risks of hospitalization for upper gastrointestinal bleeding in selective serotonin reuptake inhibitors users after Helicobacter pylori eradication therapy: a propensity score matching analysis.
    Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15507.
    >> Share

    August 2019
  60. MIN YW, Kang D, Shin JY, Kang M, et al
    Use of proton pump inhibitors and risk of cholangitis: a nationwide cohort study.
    Aliment Pharmacol Ther. 2019 Aug 25. doi: 10.1111/apt.15466.
    >> Share

  61. ARGUETA EA, Moss SF
    Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment.
    Aliment Pharmacol Ther. 2019;50:331-332.
    >> Share

  62. LU H, Graham DY
    Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment-authors' reply.
    Aliment Pharmacol Ther. 2019;50:332.
    >> Share

  63. RONKAINEN J, Aro P, Walker MM, Agreus L, et al
    Editorial: the overlap between dyspepsia and gastro-oesophageal reflux-is duodenal eosinophilia the missing link? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:455-456.
    >> Share

  64. KANNO T, Moayyedi P
    Editorial: the overlap between dyspepsia and gastro-oesophageal reflux-is duodenal eosinophilia the missing link?
    Aliment Pharmacol Ther. 2019;50:454-455.
    >> Share

    June 2019
  65. TEPLER A, Narula N, Peek RM Jr, Patel A, et al
    Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Jun 5. doi: 10.1111/apt.15306.
    >> Share

  66. HOLMBERG D, Santoni G, Xie S, Lagergren J, et al
    Gastric bypass surgery in the treatment of gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2019 Jun 4. doi: 10.1111/apt.15274.
    >> Share

    May 2019
  67. RONKAINEN J, Aro P, Walker MM, Agreus L, et al
    Duodenal eosinophilia is associated with functional dyspepsia and new onset gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2019 May 20. doi: 10.1111/apt.15308.
    >> Share

  68. CORFE BM, Chowdry J, Russell JM, Race C, et al
    Letter: studies of salivary pepsin in patients with gastro-oesophageal reflux disease. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1249-1250.
    >> Share

  69. RACE C, Chowdry J, Russell JM, Corfe BM, et al
    Studies of salivary pepsin in patients with gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2019;49:1173-1180.
    >> Share

  70. DETTMAR PW, Woodcock AD, Wilcox MD, Chater PI, et al
    Letter: studies of salivary pepsin in patients with gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2019;49:1248-1249.
    >> Share

  71. HOGH MB, Kronborg C, Moller Hansen J, Wildner-Christensen M, et al
    Editorial: population-based testing for Helicobacter pylori in Western countries. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1361.
    >> Share

  72. VAKIL N
    Editorial: population-based testing for Helicobacter pylori in Western countries.
    Aliment Pharmacol Ther. 2019;49:1360.
    >> Share

    April 2019
  73. CHEN Q, Long X, Ji Y, Liang X, et al
    Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
    Aliment Pharmacol Ther. 2019 Apr 24. doi: 10.1111/apt.15273.
    >> Share

  74. WONG GL, Ma AJ, Deng H, Ching JY, et al
    Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding.
    Aliment Pharmacol Ther. 2019;49:912-918.
    >> Share

    March 2019
  75. HOGH MB, Kronborg C, Hansen JM, Schaffalitzky de Muckadell OB, et al
    The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.
    Aliment Pharmacol Ther. 2019 Mar 10. doi: 10.1111/apt.15193.
    >> Share

  76. LEE KJ, Son BK, Kim GH, Jung HK, et al
    Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
    Aliment Pharmacol Ther. 2019 Mar 6. doi: 10.1111/apt.15185.
    >> Share

  77. YUAN Y, Leontiadis GI
    Editorial: ulcer-related vs non-ulcer-nonvariceal upper gastrointestinal bleeding-which has worse outcomes?
    Aliment Pharmacol Ther. 2019;49:818-819.
    >> Share

    February 2019
  78. DONG R, Xu X, Yu L, Ding H, et al
    Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough.
    Aliment Pharmacol Ther. 2019 Feb 10. doi: 10.1111/apt.15169.
    >> Share

    January 2019
  79. SEY MSL, Mohammed SB, Brahmania M, Singh S, et al
    Comparative outcomes in patients with ulcer- vs non-ulcer-related acute upper gastrointestinal bleeding in the United Kingdom: a nationwide cohort of 4478 patients.
    Aliment Pharmacol Ther. 2019 Jan 9. doi: 10.1111/apt.15092.
    >> Share

  80. OSHIMA T, Arai E, Taki M, Kondo T, et al
    Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
    Aliment Pharmacol Ther. 2019;49:140-146.
    >> Share

    November 2018
  81. BONDERUP OK
    Letter: the association between the use of different proton pump inhibitors and microscopic colitis should be re-evaluated-author's reply.
    Aliment Pharmacol Ther. 2018;48:1036.
    >> Share

  82. TAO P, Wang S
    Letter: the association between the use of different proton pump inhibitors and microscopic colitis should be re-evaluated.
    Aliment Pharmacol Ther. 2018;48:1035.
    >> Share


  83. Retraction: Randomised clinical trial: The clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China by J.
    Aliment Pharmacol Ther. 2018;48:1039.
    >> Share

  84. PONZETTO A, Figura N
    Letter: proton pump inhibitors and the risk of hepatocellular carcinoma.
    Aliment Pharmacol Ther. 2018;48:1164-1165.
    >> Share

  85. SHAO YJ, Wu SY
    Letter: association between proton pump inhibitors and the risk of hepatocellular carcinoma-authors' reply.
    Aliment Pharmacol Ther. 2018;48:1165-1166.
    >> Share

    October 2018
  86. RIBOLSI M, Cicala M, Zentilin P, Neri M, et al
    Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Aliment Pharmacol Ther. 2018 Oct 7. doi: 10.1111/apt.14986.
    >> Share

  87. ZHAO J, Hua L, Li N, An R, et al
    Letter: proton pump inhibitors use and risk of hepatocellular carcinoma: A meta-analysis of observational studies.
    Aliment Pharmacol Ther. 2018;48:886-888.
    >> Share

  88. KROL R, van Oijen MGH
    Editorial: proton pump inhibitors (PPIs) and microscopic colitis.
    Aliment Pharmacol Ther. 2018;48:880-881.
    >> Share

    September 2018
  89. BATCHELOR R, Kumar R, Gilmartin-Thomas JFM, Hopper I, et al
    Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel.
    Aliment Pharmacol Ther. 2018 Sep 4. doi: 10.1111/apt.14955.
    >> Share

  90. SHAO YJ, Wu SY
    Letter: cohort study examining the association between proton pump inhibitors therapy and risk of hepatocellular carcinoma in Taiwan-authors' reply.
    Aliment Pharmacol Ther. 2018;48:690-691.
    >> Share

  91. LIAO KF, Lai HC, Lin CL, Lai SW, et al
    Letter: cohort study examining the association between proton pump inhibitor therapy and risk of hepatocellular carcinoma in Taiwan.
    Aliment Pharmacol Ther. 2018;48:689-690.
    >> Share

    August 2018
  92. WALDUM HL
    Editorial: proton pump inhibitors (PPIs) and primary liver cancer.
    Aliment Pharmacol Ther. 2018;48:380-381.
    >> Share

    July 2018
  93. BONDERUP OK, Nielsen GL, Dall M, Pottegard A, et al
    Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study.
    Aliment Pharmacol Ther. 2018 Jul 23. doi: 10.1111/apt.14916.
    >> Share

  94. GATTA L, Scarpignato C
    Editorial: Helicobacter pylori resistance and sequential therapy-authors' reply.
    Aliment Pharmacol Ther. 2018;48:96-97.
    >> Share

  95. SIDDIQUE O, Moss SF
    Editorial: Helicobacter pylori resistance and sequential therapy.
    Aliment Pharmacol Ther. 2018;48:95-96.
    >> Share

    June 2018
  96. SHAO YJ, Chan TS, Tsai K, Wu SY, et al
    Association between proton pump inhibitors and the risk of hepatocellular carcinoma.
    Aliment Pharmacol Ther. 2018 Jun 13. doi: 10.1111/apt.14835.
    >> Share

  97. ZHAO J, Wang JM, Zhang XW, An R, et al
    Letter: proton pump inhibitor use and risk of fracture.
    Aliment Pharmacol Ther. 2018;47:1570-1571.
    >> Share

  98. SUGIYAMA T
    Letter: association between proton pump inhibitor use and fracture risk - causality or confounding?
    Aliment Pharmacol Ther. 2018;47:1569-1570.
    >> Share

    May 2018
  99. TRAN KT, McMenamin UC, Hicks B, Murchie P, et al
    Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
    Aliment Pharmacol Ther. 2018 May 9. doi: 10.1111/apt.14796.
    >> Share

  100. TSIPOTIS E, Leontiadis GI
    Editorial: the prevalence of Helicobacter pylori infection worldwide-knowns and unknowns.
    Aliment Pharmacol Ther. 2018;47:1330-1331.
    >> Share

  101. ZAMANI M, Derakhshan MH, Zamani V, Shokri-Shirvani J, et al
    Editorial: the prevalence of Helicobacter pylori infection worldwide-knowns and unknowns. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1331-1332.
    >> Share

  102. TRIGGS JR, Kahrilas PJ
    Editorial: symptom association probability during reflux testing-what is the gain?
    Aliment Pharmacol Ther. 2018;47:1317-1318.
    >> Share

    April 2018
  103. VENERITO M, Schneider C, Costanzo R, Breja R, et al
    Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors.
    Aliment Pharmacol Ther. 2018 Apr 14. doi: 10.1111/apt.14652.
    >> Share

  104. TABIBIAN JH, Lindor KD
    Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses?
    Aliment Pharmacol Ther. 2018;47:1226-1227.
    >> Share

  105. BETTINGER D, Thimme R, Boettler T
    Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1228-1229.
    >> Share

    March 2018
  106. GATTA L, Scarpignato C, Fiorini G, Belsey J, et al
    Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains.
    Aliment Pharmacol Ther. 2018 Mar 14. doi: 10.1111/apt.14597.
    >> Share

  107. TORVINEN-KIISKINEN S, Tolppanen AM, Koponen M, Tanskanen A, et al
    Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study.
    Aliment Pharmacol Ther. 2018 Mar 6. doi: 10.1111/apt.14589.
    >> Share

    February 2018
  108. ZAMANI M, Ebrahimtabar F, Zamani V, Miller WH, et al
    Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2018 Feb 12. doi: 10.1111/apt.14561.
    >> Share

  109. SUGIYAMA T
    Letter: proton pump inhibitor use and fracture risk.
    Aliment Pharmacol Ther. 2018;47:449-450.
    >> Share

    January 2018
  110. BETTINGER D, Martin D, Rieg S, Schultheiss M, et al
    Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess.
    Aliment Pharmacol Ther. 2018 Jan 12. doi: 10.1111/apt.14512.
    >> Share

  111. HU Y, Wan JH, Li XY, Zhu Y, et al
    Editorial: recurrence of Helicobacter pylori infection-still the same after all these years... Authors' reply.
    Aliment Pharmacol Ther. 2018;47:132-133.
    >> Share

  112. SHAH E, Chey WD
    Editorial: recurrence of Helicobacter pylori infection-still the same after all these years....
    Aliment Pharmacol Ther. 2018;47:131-132.
    >> Share

  113. MACNAUGHTAN J, Jalan R
    Editorial: proton pump inhibitor therapy and liver disease progression-more cause for concern?
    Aliment Pharmacol Ther. 2018;47:304-305.
    >> Share

    December 2017
  114. SONG M, Camargo MC, Weinstein SJ, Murphy G, et al
    Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.
    Aliment Pharmacol Ther. 2017 Dec 15. doi: 10.1111/apt.14471.
    >> Share

    November 2017
  115. BROERS C, Tack J, Pauwels A
    Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease.
    Aliment Pharmacol Ther. 2017 Nov 29. doi: 10.1111/apt.14416.
    >> Share

  116. HWANG YJ, Kim N, Lee HS, Lee JB, et al
    Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years.
    Aliment Pharmacol Ther. 2017 Nov 29. doi: 10.1111/apt.14424.
    >> Share

  117. LI DK, Yan P, Abou-Samra AB, Chung RT, et al
    Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
    Aliment Pharmacol Ther. 2017 Nov 3. doi: 10.1111/apt.14391.
    >> Share

    September 2017
  118. HU Y, Wan JH, Li XY, Zhu Y, et al
    Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori.
    Aliment Pharmacol Ther. 2017 Sep 11. doi: 10.1111/apt.14319.
    >> Share

  119. FRASER AG
    Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori.
    Aliment Pharmacol Ther. 2017;46:550-551.
    >> Share

  120. JUNG YS, Kim EH, Park CH
    Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply.
    Aliment Pharmacol Ther. 2017;46:551-552.
    >> Share

  121. KAGAWA T, Iwamuro M, Inaba T
    Letter: a potassium-competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection-induced artificial ulcers after treatment of gastric neoplasms-authors' reply.
    Aliment Pharmacol Ther. 2017;46:566.
    >> Share

  122. BAN H, Sugimoto M, Otsuka T, Murata M, et al
    Letter: a potassium-competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection-induced artificial ulcers after treatment of gastric neoplasms.
    Aliment Pharmacol Ther. 2017;46:564-565.
    >> Share

  123. KOUNTOURAS J, Polyzos SA, Katsinelos P, Doulberis M, et al
    Letter: Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease.
    Aliment Pharmacol Ther. 2017;46:637-638.
    >> Share

    August 2017
  124. KWON Y, Jeon S, Nam S, Shin I, et al
    Helicobacter pylori infection and serum level of pepsinogen are associated with the risk of metachronous gastric neoplasm after endoscopic resection.
    Aliment Pharmacol Ther. 2017 Aug 11. doi: 10.1111/apt.14263.
    >> Share

  125. ZAGARI RM, Rabitti S, Greenwood DC, Eusebi LH, et al
    Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis.
    Aliment Pharmacol Ther. 2017 Aug 7. doi: 10.1111/apt.14248.
    >> Share

  126. SAFIRI S, Ayubi E
    Letter: functional dyspepsia is associated with duodenal eosinophilia in an Australian paediatric cohort-methodological issues to avoid misinterpretation.
    Aliment Pharmacol Ther. 2017;46:387.
    >> Share

    June 2017
  127. CHEN WC, Lin KH, Huang YT, Tsai TJ, et al
    The risk of lower gastrointestinal bleeding in low-dose aspirin users.
    Aliment Pharmacol Ther. 2017;45:1542-1550.
    >> Share

    May 2017
  128. GENTA RM, Turner KO, Sonnenberg A
    Demographic and socioeconomic influences on Helicobacter pylori gastritis and its pre-neoplastic lesions amongst US residents.
    Aliment Pharmacol Ther. 2017 May 25. doi: 10.1111/apt.14162.
    >> Share

  129. LAURSEN SB, Leontiadis GI, Stanley AJ, Hallas J, et al
    The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding.
    Aliment Pharmacol Ther. 2017 May 23. doi: 10.1111/apt.14153.
    >> Share

  130. YI S, Lee H, Jang SB, Byun HM, et al
    A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
    Aliment Pharmacol Ther. 2017 May 21. doi: 10.1111/apt.14148.
    >> Share

  131. JUNG YS, Kim EH, Park CH
    Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2017 May 12. doi: 10.1111/apt.14130.
    >> Share

  132. COYLE C, Crawford G, Wilkinson J, Thomas SJ, et al
    Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
    Aliment Pharmacol Ther. 2017 May 2. doi: 10.1111/apt.14064.
    >> Share

    April 2017
  133. SUGIMOTO M, Ban H, Hira D, Kamiya T, et al
    Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan.
    Aliment Pharmacol Ther. 2017;45:1009-1010.
    >> Share

    March 2017
  134. MASTRACCI L, Fiocca R, Engstrom C, Attwood S, et al
    The dynamics of the oesophageal squamous epithelium 'normalisation' process in patients with gastro-oesophageal reflux disease treated with long-term acid suppression or anti-reflux surgery.
    Aliment Pharmacol Ther. 2017 Mar 21. doi: 10.1111/apt.14038.
    >> Share

  135. VAKIL N, Vieth M, Wernersson B, Wissmar J, et al
    Diagnosis of gastro-oesophageal reflux disease is enhanced by adding oesophageal histology and excluding epigastric pain.
    Aliment Pharmacol Ther. 2017 Mar 20. doi: 10.1111/apt.14028.
    >> Share

  136. TALEBI BEZMIN ABADI A
    Letter: more studies are needed to elucidate any association between Helicobacter pylori infection and Barrett's metaplasia.
    Aliment Pharmacol Ther. 2017;45:764-765.
    >> Share

    February 2017
  137. SHAW J, Bajaj JS
    Editorial: should the inappropriate use of proton pump inhibitors be a quality assurance issue in cirrhotic patients?
    Aliment Pharmacol Ther. 2017;45:476-477.
    >> Share

  138. CHEN PY, Wu MS, Liou JM
    Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:573.
    >> Share

  139. ZAMANI M, Shokri-Shirvani J, Zamani V
    Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2017;45:572-573.
    >> Share

  140. AHN JS, Sinn DH, Son HJ, Gwak GY, et al
    Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply.
    Aliment Pharmacol Ther. 2017;45:577-578.
    >> Share

  141. KOUNTOURAS J, Polyzos SA, Kapetanakis N, Katsinelos P, et al
    Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia.
    Aliment Pharmacol Ther. 2017;45:576-577.
    >> Share

    January 2017
  142. SCHIAVON LL, Silva TE, Fischer J, Narciso-Schiavon JL, et al
    Letter: proton pump inhibitors and prognosis of cirrhosis - searching for the balance point.
    Aliment Pharmacol Ther. 2017;45:378-379.
    >> Share

    November 2016
  143. MIWA H, Uedo N, Watari J, Mori Y, et al
    Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13876.
    >> Share

  144. SONNENBERG A, Turner KO, Spechler SJ, Genta RM, et al
    The influence of Helicobacter pylori on the ethnic distribution of Barrett's metaplasia.
    Aliment Pharmacol Ther. 2016 Nov 9. doi: 10.1111/apt.13854.
    >> Share

    October 2016
  145. COLE HL, Pennycook S, Hayes PC
    The impact of proton pump inhibitor therapy on patients with liver disease.
    Aliment Pharmacol Ther. 2016 Oct 23. doi: 10.1111/apt.13827.
    >> Share

  146. SAVARINO E, Girardin G, Della Coletta M, Ottonello A, et al
    Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease. Authors' reply.
    Aliment Pharmacol Ther. 2016;44:912-3.
    >> Share

  147. MOLINA-INFANTE J, Katzka DA, Spechler SJ
    Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2016;44:911-2.
    >> Share

    September 2016
  148. MARTIN FC, Chenevix-Trench G, Yeomans ND
    Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors.
    Aliment Pharmacol Ther. 2016 Sep 15. doi: 10.1111/apt.13800.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016